Arctic Bioscience – Q1 2023 Operational update – HeROPA clinical trial approved in all 5 countries and ongoing
Highlights Q1 2023: · The phase IIb HeROPA clinical trial approved in all the five European countries where the trial will be conducted · More than two-thirds of the planned clinical trial sites (clinics) in the five countries activated · Future opportunities in the microalgae segment through the acquisition of Arctic Algae AS · Growth in Nutra sales revenues of 39 % compared to Q1 2022 · Solid financial position with NOK 130,6 million in cash by end of Q1 2023During the first quarter of 2023, the foundation was laid for exciting future opportunities with new customers in